New clinical guidelines, late-breaking trials, artificial intelligence, and an increasing focus on cardiometabolic and precision medicine are set to shape discussions at ESC Congress 2026 in Munich.
The ESC Congress 2026 will bring the international cardiovascular community to Munich, Germany, from August 28–31, with a scientific program spanning new clinical evidence, emerging technologies, and practical approaches to improving cardiovascular care.1
This year, several themes stand out, from the release of major new clinical guidelines to a dedicated spotlight on artificial intelligence (AI). The meeting will also feature a record 59 trials across 12 Hot Line sessions, providing first presentations of findings that could influence future clinical practice.1,2
Don’t miss out on hearing about our latest peer-reviewed articles, expert opinions, conference news, podcasts and more.
New guidelines take center stage
Three new ESC Clinical Practice Guidelines will be released during the congress: the 2026 ESC Guidelines for the Management of Heart Failure, 2026 ESC Guidelines on Cardiac Rehabilitation, and 2026 ESC Guidelines for the Management of Cardiovascular Disease and Chronic Kidney Disease.1
The congress will also see the release of the 5th Universal Definition of Myocardial Infarction, developed in collaboration with the American College of Cardiology, American Heart Association, and World Heart Federation.1
Rather than focusing only on publication of the documents themselves, the program will include interactive “Ask the Task Force” sessions with guideline authors and “Guidelines in Practice” sessions using clinical cases to explore how recommendations can be translated into everyday care.1
The updated heart failure guidance is likely to be particularly closely watched given the pace of change in the field and the growing range of therapies now available across the spectrum of heart failure.
Late-breaking evidence to watch
Clinical trial results remain one of the biggest draws at ESC Congress, and 2026 will feature an unprecedented 59 trials across 12 Hot Line sessions.2
The program spans acute coronary syndromes, prevention, cardiomyopathy, and other major areas of cardiovascular medicine, with studies examining both established treatments and newer therapeutic strategies.
Among the most anticipated are trials investigating factor XIa inhibition following acute coronary syndromes, faster diagnosis of myocardial infarction, transthyretin amyloid cardiomyopathy, hypertrophic cardiomyopathy, and statin use in healthy adults aged over 70 years.2
AI moves into clinical practice
AI is the official Spotlight of ESC Congress 2026, reflecting the growing role of digital technologies across cardiovascular medicine.1
Sessions will explore how AI is already being applied in areas including ECG interpretation, cardiovascular imaging, and risk prediction, as well as the practical challenges involved in integrating these tools into clinical workflows.1
The wider Digital Cardiology Track will cover machine learning, big-data applications, predictive modeling, and AI-supported drug discovery, alongside issues including ethics, interoperability, and data governance.1
The focus is therefore likely to move beyond whether AI has a role in cardiology toward the more practical questions of where it adds value, how it should be implemented, and how clinicians can ensure its safe and responsible use.
Cardiometabolic care continues to converge
The increasingly close relationship between cardiovascular, metabolic, and renal disease is another prominent theme in the 2026 program.
A dedicated Cardiometabolic Track will examine the interplay between obesity, diabetes, dyslipidemia, and hypertension, including emerging metabolic therapies and interventional approaches.1
The new guideline addressing cardiovascular disease and chronic kidney disease further reflects this shift toward more integrated management of patients whose cardiovascular risk cannot easily be considered within a single specialty.1
Looking toward the next generation of cardiovascular therapies
While much of ESC Congress is focused on evidence that can inform current practice, the New Horizons in Cardiology Track will look further ahead.
Sessions will explore emerging diagnostic and therapeutic approaches, including biological therapies and gene-editing technologies, across conditions such as heart failure, hypertension, and hyperlipidemia.1
Together with late-breaking studies evaluating newer disease-modifying treatments, the track highlights the continuing movement toward more targeted and potentially longer-lasting approaches to cardiovascular disease.
→ Take a look at the full ESC Congress 2026 programme here
With new guidelines, emerging technologies, and a substantial program of late-breaking research, ESC Congress 2026 will provide an early indication of which innovations are moving closer to routine cardiovascular practice, and which questions remain to be answered.
References
- European Society of Cardiology. ESC Congress 2026 Scientific Programme. Accessed August 7, 2026.
- European Society of Cardiology. Hot Lines revealed – the trials that will make the headlines at ESC Congress 2026. Published July 23, 2026.
Cite: ESC Congress 2026 preview. touchCARDIO. August 7, 2026.
Disclosure: This content has been developed independently by Touch Medical Media for touchCARDIO, utilizing AI as an editorial tool (Claude (Sonnet 5) [Large language model] https://claude.ai). No funding was received in the publication of this article.
Editor: Nicola Cartridge, Director of Content
